Panzer S, Zeitelhuber U, Hach V, Brackmann H H, Niessner H, Mueller-Eckhardt C
Transfusion. 1986 Jan-Feb;26(1):69-72. doi: 10.1046/j.1537-2995.1986.26186124036.x.
Five patients with severe hemophilia A receiving long-term treatment with commercial factor VIII concentrates developed severe immune thrombocytopenia (ITP, platelet counts less than 20 X 10(9)/l). Concomitantly, they presented with a marked elevation of serum IgG concentrations (mean, 2364 mg/dl;range, 1712-2954 mg/dl). In four patients, the T helper to suppressor cell ratio was below 1. Treatment with high-dose intravenous immunoglobulin (IgG, 7s) at doses of 0.2g (n = 2) or 0.4g (n = 3) per kg of body weight on 5 consecutive days was effective immediately. The bleeding tendency ceased and platelet counts rose transiently. In three cases, treatment was repeatedly effective and patients underwent uneventful splenectomies. Thus, high-dose IgG therapy may serve as a life-saving agent in patients with severe hemophilia complicated by ITP.
5例接受市售VIII因子浓缩物长期治疗的重度甲型血友病患者发生了严重免疫性血小板减少症(ITP,血小板计数低于20×10⁹/L)。同时,他们血清IgG浓度显著升高(平均2364mg/dl;范围1712 - 2954mg/dl)。4例患者辅助性T细胞与抑制性T细胞的比例低于1。连续5天给予每公斤体重0.2g(n = 2)或0.4g(n = 3)的高剂量静脉注射免疫球蛋白(IgG,7s)治疗立即起效。出血倾向停止,血小板计数短暂上升。3例患者治疗反复有效,且顺利接受了脾切除术。因此,高剂量IgG疗法可作为重度血友病并发ITP患者的一种挽救生命的药物。